Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

Native American infants, with an overall incidence and severity of adverse events (AEs) that were similar between the motavizumab and the placebo groups. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of hypersensitivity related skin rashes within two days of dosing were seen in about one percent of treated children in the motavizumab group.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pediatric patients and met its secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... 28, 2014 The new ... Market (products, applications, techniques, end users and Geography) ... Forecast, 2013 - 2020," indicates that the global ... 2020 registering a CAGR of 9.8% from 2014 ... and cost effectiveness over alternative diagnostic techniques are ...
(Date:8/28/2014)... Aug. 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), ... obtaining FDA clearance for and commercializing its CE Marked ... aiding in identifying children, adolescent, and young adult patients ... for appendicitis, today announced it will present at three ... Annual Global Investment Conference being held in ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... 2010 Kensey Nash Corporation (Nasdaq: KNSY ... in November.   Michael Celano, Kensey Nash,s ... the Oppenheimer 21st Annual Healthcare Conference at the Waldorf ... p.m. (ET).  To hear the live webcast of the ...
... (Nasdaq: SLTM ), a global leader in the ... ended September 30, 2010. Revenue for the third quarter was ... as compared to the third quarter 2009 revenue of $17.8 ... by a year-over-year 40% increase in sales of treatment tips ...
Cached Medicine Technology:Solta Medical Reports Third Quarter 2010 Results 2Solta Medical Reports Third Quarter 2010 Results 3Solta Medical Reports Third Quarter 2010 Results 4Solta Medical Reports Third Quarter 2010 Results 5Solta Medical Reports Third Quarter 2010 Results 6Solta Medical Reports Third Quarter 2010 Results 7Solta Medical Reports Third Quarter 2010 Results 8
(Date:8/28/2014)... Solid-head power toothbrushes retain less bacteria compared ... University of Texas Health Science Center at Houston ... study are published in the August issue of ... professor at the UTHealth School of Dentistry, Donna ... were lower in the solid-head toothbrush group than ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... Initial human testing of an investigational vaccine to prevent ... National Institute of Allergy and Infectious Diseases (NIAID), part ... trial will begin initial human testing of a vaccine ... the experimental vaccine,s safety and ability to generate an ... place at the NIH Clinical Center in Bethesda, Maryland. ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
... today announced their plans to expand their online video ... overwhelming success achieved by the website since its inception ... library has been visited by physicians from 64 different ... from repeat visits and the average length of stay ...
... Recent Developments at Major Patenting Authorities WorldwidePHILADELPHIA and LONDON, ... Thomson Reuters today released its 2009 Patent Focus ... Intellectual Asset Management magazine, and published in the ... , this report explores recent activities at each of ...
... SEATTLE, Feb. 17 Cell Therapeutics, Inc. (Nasdaq and ... a press release in Italy in response to information ... CTI,s business operations and financial condition, which was also ... February 17, 2009, the Borsa Italiana has confirmed that ...
... 17 The civil rights movement gained a ... of Representatives voted Feb. 17 to recognize the ... by American Life League Associate group North Dakota ... of The Personhood of Children Act (House Resolution ...
... Consumers who purchased raw milk from the Swiss Villa ... after Feb. 9 are advised to discard it immediately ... Secretary Dennis Wolff said today. Raw milk has not ... a result of the potential contamination, but if people ...
... Shenghuo,Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China ... 10, 2009, it received a,deficiency letter from the ... the,"Exchange") stating that the Company was not in ... standards due to the Company,s failure to,hold an ...
Cached Medicine News:Health News:Physicians online library is a worldwide hit 2Health News:Physicians online library is a worldwide hit 3Health News:Thomson Reuters Releases 2009 Patent Focus Report 2Health News:Cell Therapeutics to Resume Trading on MTA and NASDAQ 2Health News:North Dakota Personhood Bill Passes State House 51-41 2Health News:Consumer Advisory: Agriculture Department Warns of Tainted Raw Milk Sold By Dauphin County Dairy 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 3
... ROM Elbow Orthosis features aluminum cuffs that ... arm. To ensure proper joint alignment, unique ... and distal adjustments to cuff position. Cuffs ... is necessary for use with contractures.,The hinge ...
... Brace is designed to handle post-op elbow ... The Bledsoe Extender Arm Brace should be ... of the elbow is desired. In most ... be formed, fitted and adjusted in 5 ...
... This controlled stretch ankle support helps reduce ... of motion. It is easy to apply ... its slim design fits easily into shoes. ... the ankle, and provide side-to-side support and stability. ...
... ankle support provides excellent com-pression and ... motion. The anatomically sculpted visco-elastic ... weakened or injured soft tissues under ... to apply - slips on like ...
Medicine Products: